Guidelines
Aim of cGvHD treatment and general considerations
NCCN guidelines for the management of cGvHD3
*central line access, IV infusion, injection, pill that is convenient for patients.
BD, twice daily; cGvHD, chronic-graft-versus host disease; CR, complete response; CS, corticosteroids; CNIs, calcineurin inhibitors; ECP, Electrocorproeal photopheresis; FFS, failure-free survival; MMF, Mycophenolic acid; NR, not registered; OD, once daily; ORR, overall response rate; PR, partial response; QoL, quality of life; SR, steroid refractory; SOC, standard of care; URTI, upper respiratory tract infection; NCCN, National Comprehensive Cancer Network; EBMT, European Society for Blood and Marrow Transplantation.
- Hamilton BK. Hematology Am Soc Hematol Educ Program. 2021;2021(1):648-654.;
- Malard F, et al. Am J Hematol. 2023;98(10):1637-1644;
- Hematopoietic Cell Transplantation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;
- Flowers MED, et al. Blood. 2015;125(4):606-615.;
- Dignan FL, et al. British journal of haematology. 2012;158(1):46-61.;
- Zeiser R. J Clin Oncol. 2023;41(10):1820-1824.;. Hamilton BK. Hematology Am Soc Hematol Educ Program. 2021;2021(1):648-654.
- Kim D.D.H et al. Curr Oncol. 2024;31:1426-1444.;
- Milkos D et al., Blood. 2017;130:2243-2250.;
- Cutler C et al. Blood. 2021;138:2278-2289.;
- Zeiser R et al. N Engl J Med. 2021;385:228-238.
Bevestig uw status
Bevestig uw status
Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal
speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een ljst met
evenementen en tools en diensten voor uw dagelijkse praktik.